Stoke Therapeutics, a leading biopharmaceutical firm, has announced significant strides in its clinical programs, particularly for zorevunersen, a groundbreaking treatment for Dravet syndrome. The company's second-quarter 2026 earnings call revealed the successful completion of patient enrollment for the Phase III EMPEROR study, a pivotal moment that positions zorevunersen for potential market entry by early 2028. This advancement, coupled with strong patient retention rates in ongoing trials and robust financial backing, underscores Stoke's commitment to addressing severe genetic disorders. Furthermore, the company is actively expanding its pipeline with promising developments in Autosomal Dominant Optic Atrophy (ADOA) and SYNGAP1-related disorders, showcasing a broad and impactful research agenda.
Latest Developments from Stoke Therapeutics' Q2 2026 Earnings Call
On Monday, August 3, 2026, during the second-quarter earnings call, Stoke Therapeutics' leadership team, including Chief Financial Officer Thomas Leggett, Chief Executive Officer Ian Smith, Chief Medical Officer Barry Ticho, and Chief Patient Officer Jason Hoitt, provided crucial updates. The primary focus was on the EMPEROR study for zorevunersen, which has successfully enrolled 162 patients, marking a significant milestone in its journey toward a Phase III readout in Q3 2027. This rapid enrollment, achieved in just 10 months, reflects both the urgent unmet need in Dravet syndrome and the medical community's enthusiasm for zorevunersen's potential.
Notably, the EMPEROR study boasts a 0% patient discontinuation rate to date, far surpassing the initial 15% assumed in statistical powering. This exceptional retention rate further solidifies confidence in the therapy's safety and tolerability. As of June 2026, 145 patients have progressed through week 8 of treatment, receiving two 70-milligram loading doses of zorevunersen or a sham control. Additionally, 60 patients have completed their week 28 visit, reaching the critical time point for measuring changes in major motor seizure frequency.
Stoke Therapeutics is also preparing for a rolling New Drug Application (NDA) submission, slated to commence in Q1 2027 with the chemistry, manufacturing, and controls module, followed by the clinical data in Q3 2027. A pre-NDA meeting with the FDA is scheduled for late 2026 to discuss the submission sequence, the statistical analysis plan (SAP), and updated five-year open-label extension (OLE) data, which has shown durable seizure control and sustained improvements in cognition and behavior.
Financially, Stoke Therapeutics reported a pro forma cash position of $420 million, including $65.7 million from a recent stock sale. This capital is expected to fund operations through the anticipated U.S. commercial launch of zorevunersen in early 2028. Second-quarter revenue was $9.3 million, with a net loss of $61.6 million. Research and development expenses increased to $49.5 million due to zorevunersen's advancement, and sales, general, and administrative expenses rose to $25.3 million in preparation for commercialization.
Beyond Dravet syndrome, Stoke is advancing STK-002 for ADOA. Three patients have completed dosing in the first cohort of the Phase I OSPREY study, with dose escalation to the second cohort initiating in August 2026. Initial safety and efficacy results for STK-002 are expected in the first half of 2027. The company is also pursuing five drug candidates for SYNGAP1-related disorders, aiming to select a clinical development candidate in 2027. Additionally, new studies for zorevunersen in infants under 24 months and adults are planned for initiation in the latter half of 2026.
Jason Hoitt emphasized the concentrated commercial market for Dravet syndrome, with 50% of the estimated 16,000 U.S. patients treated at the top 50 sites, many of which are already involved in zorevunersen trials. This allows for a lean commercial infrastructure of approximately 25 sales representatives. The company believes that zorevunersen's breakthrough therapy designation supports a broad label and efficient adoption, while long-term OLE data is proving highly compelling to both payers and healthcare providers.
The call underscored Stoke Therapeutics' dedication to pioneering treatments for genetic neurological disorders, backed by robust clinical data and a strategic commercialization plan.
The advancements at Stoke Therapeutics illustrate a profound commitment to transforming the lives of individuals afflicted with severe genetic disorders. The impressive patient retention and progress in the EMPEROR study for zorevunersen are particularly encouraging, signaling not only the potential efficacy of the treatment but also its favorable tolerability profile. As a journalist covering medical innovations, it's inspiring to witness how targeted therapies are increasingly moving beyond symptom management to address the root genetic causes of diseases. The focus on long-term outcomes, particularly the Vineland scores indicating improvements in cognition and behavior, highlights a holistic approach to patient care that extends beyond seizure reduction, offering a glimmer of hope for a more neurotypical developmental trajectory for children with Dravet syndrome. This comprehensive strategy, combined with a meticulous approach to regulatory submissions and a deep understanding of market dynamics, positions Stoke Therapeutics as a beacon of progress in the biopharmaceutical landscape.
